03.05.2019 Issue 441

   
Visit HealthEconomics.Com Subscribe to Newsletters  |  Contact Us  |  Forward to a Friend
Sponsored by:

This Week's HEOR Round-up
The Top Story in HEOR: Latest Headlines in HEOR:

Shafrin: ICER Tackling 'Pressing Issue'
With Value-Over-Time Reports

Thursday, February 28

ICER's decision to do reports on a drug’s value over time is one that "addresses a pressing issue," according to Jason Shafrin, a health care economist.

Survey: More Americans Blame Pharma for High Prices

Podcast Spotlights Artificial Intelligence in Oncology

Fendrick, Klein Back Drug Rebate Proposal

eMAX Health Welcomes New Member to Senior Leadership Team

Sen. Durbin Slams Pharma Over Opioid Crisis


Senior Principal, Pricing Market Access

Senior Systematic Reviewer

Sr Principal/Principal Health Economics

Cardiovascular Medical Content Writer with AMCP Dossier and HEOR Knowledge

Industry Spotlight


Conferences Webinars
Patients as Partners U.S.
    March 11-12, Philadelphia, Pennsylvania

E-Prescribing and Electronic Health Records
    March 12-13, Philadelphia, Pennsylvania

Causal Inference in Observational Studies and Clinical Trials Affected by Treatment Switching: A Practical Hands-on Workshop
    March 18-21, Tyrol, Austria

Statistical Methods in Economic Evaluation for Health Technology Assessment
    March 18-19, York, England

Leveraging RWE to Drive Patient Access in the Age of Big Data Analytics
    March 5

Designing Benefits and Payment Models for Innovative High-Investment Medications - Proceedings from the AMCP Partnership Forum
    March 12

What Do Value Assessments Miss? Rethinking Value Using New Health Economics Evidence
    March 13

Future Proofing for the 2020s: Market Access Trends
    March 14


Conference of the Week Webinar of the Week Job of the Week Link of the Week

Syndicated Reports White Papers
Review of Influence: The Institute for Clinical and Economic Review

Innovative Drugs: Mapping the Pricing and Reimbursement Landscape

Orphan Drugs: European Payer Perspectives

Do Payers Really Want Pay-for-Performance?

Payer Engagement: Benchmarking Team Structure and Activity

Benchmarking Market Access Strategies for High-Cost Drugs, Biologics

Blockchain: Transformational Change for Pharma?

2018 Specialty Drug Trends

The Global Use of Medicine in 2019 and Outlook to 2023

Breaking Through the Hype of Real-World Evidence

Time to Market: Accelerating Market Access

Orphan Drugs in the United States

Charting Real World Data and Evidence – Activity and Capabilities (2018)


 
Special Thanks to Our Partners:
                   Truven         
              Evidera    HealthCore    University of FL
      Xcenda    OM1    Parexel    Jefferson    Dymaxium    
      Precision Xtract    Pharmerit    eMax Health    Sciformix
       Evidence Partners     ICON
Share this newsletter on social media:

Email Twitter Facebook LinkedIn